Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 6, 2025
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
Read more at globenewswire.com
